Yahong medicine announced that all patients will be enrolled in apl-1202 phase III clinical trial in China

Arterial network (wechat: vcpeat) learned that on September 23, 2019, Yahong pharmaceutical, a global innovative drug R & D company focusing on the anti-tumor and related diseases of urogenital system, announced that the phase III clinical trial of apl-1202 in China had been completed This new drug will be used in the treatment of non muscle invasive bladder cancer It is the first oral and reversible methionine aminopeptidase II (MetAP2) inhibitor to enter clinical research in the world MetAP2 inhibitors not only inhibit the growth of tumor cells, but also inhibit tumor angiogenesis At present, apl-1202 has also entered the clinical research stage in the United States The main purpose of this phase III clinical trial is to evaluate the efficacy and safety of apl-1202 combined with chemotherapy and bladder perfusion compared with placebo combined with chemotherapy and bladder perfusion in the treatment of middle and high risk non muscular invasive bladder cancer In this clinical trial, 357 patients were recruited from 40 clinical centers nationwide "We are pleased to participate in the clinical trial of apl-1202 In the past 20 years, there has been no progress in the treatment of superficial bladder cancer This trial has the potential to significantly improve the treatment of non muscle invasive bladder cancer It's a very exciting choice to be able to provide patients with oral medication " Professor Ye Dingwei, vice president of Fudan University Cancer Hospital, the main researcher involved in the clinical study, commented that "apl-1202 brings light to patients, and I am very looking forward to the clinical application of this treatment method." "Apl-1202 has shown encouraging efficacy and safety in phase II clinical trials in China The successful completion of phase III clinical trial of the combined therapy with chemotherapy and perfusion is another important milestone in the clinical development of apl-1202 We hope to provide better treatment for patients as soon as possible " Said Pan Ke, co-founder, chairman and CEO of Yahong pharmaceutical Bladder cancer is very common all over the world According to globalcan, in 2018, the number of new bladder cancer patients worldwide was 549343, with 199922 deaths Among them, 82270 new cases of bladder cancer occurred in China At present, the standard treatment is transurethral resection of bladder tumor (TURBT) Because of the high recurrence rate of tumor after operation, BCG immunotherapy or chemotherapy drugs are needed At present, the choice of second-line treatment for recurrent patients is very limited The standard treatment for high-risk patients with perfusion failure is complete cystectomy At present, no oral drugs are approved for marketing About Yahong pharmaceutical, founded in China Pharmaceutical City, Taizhou City, Jiangsu Province in March 2010, and set up R & D center in Shanghai, it is a global innovative drug R & D company focusing on anti-tumor and related diseases of urogenital system in China Yahong pharmaceutical is determined to become the most innovative and influential pharmaceutical enterprise in the field of focus, which is most respected and trusted The company focuses on the field of urogenital, and quickly establishes a leading position in this field and carries out in-depth strategic layout Yahong pharmaceutical has fully explored the global value of first in class new drugs with independent research and development and breakthrough treatment potential Meanwhile, it has introduced new drugs that have been in the late stage of overseas development or have been listed into the Chinese market, improved product pipeline diversification and synergy, and rapidly established the leading position in the domestic market This article is reprinted by yaozhi.com The copyright belongs to the original author The purpose of reprint is to transmit more information, which does not represent the view of this platform If the content of the work, copyright and other issues are involved, please contact our website message, we will delete the content in the first time.